Literature DB >> 9176923

Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study.

V Molina Rodríguez1, R Montz Andrée, M J Pérez Castejón, R Gutiérrez Labrador, F Ferre Navarrete, J L Carreas Delgado, F J Rubia Vila.   

Abstract

There is a well recognized clinical overlap between primary and secondary neuroleptic negative symptoms in schizophrenia, but their cerebral substrates are probably different. The study of these substrates could contribute to a better understanding and management of these syndromes. In the present work, the cerebral perfusion correlates, as an indirect measure of the underlying neuronal function, of negative symptoms and parkinsonism were studied with single-photon emission tomography in a group of treatment-refractory paranoid schizophrenic patients. Perfusion ratios with respect to the homolateral cerebellum were compared with a normal database. Correlation coefficients were calculated between perfusion ratios, negative symptoms and parkinsonism scores on exploratory grounds. As a group, the patients showed a bilateral, but predominantly left-sided, hypofrontality and hypotemporality, as well as an increased perfusion in right basal ganglia. Negative symptoms scores negatively correlated with prefrontal perfusion, while parkinsonism positively correlated with the activity of primary motor and sensory cortex. These findings support the existence of different cerebral substrates for primary and secondary negative symptoms in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176923     DOI: 10.1016/s0920-9964(96)00115-6

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  9 in total

Review 1.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

Review 2.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

3.  Delusions in individuals with schizophrenia: factor structure, clinical correlates, and putative neurobiology.

Authors:  David Kimhy; Ray Goetz; Scott Yale; Cheryl Corcoran; Dolores Malaspina
Journal:  Psychopathology       Date:  2005-11-01       Impact factor: 1.944

4.  Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement.

Authors:  Vicente Molina; Juan D Gispert; Santiago Reig; Javier Sanz; Javier Pascau; Andrés Santos; Manuel Desco; Tomás Palomo
Journal:  Psychopharmacology (Berl)       Date:  2004-09-10       Impact factor: 4.530

5.  Impact cérébral structurel et fonctionnel de la Clozapine chez les patients souffrant de schizophrénie : revue systématique des études longitudinales en neuroimagerie.

Authors:  Anaïs Vandevelde; Lucie Métivier; Sonia Dollfus
Journal:  Can J Psychiatry       Date:  2020-11-02       Impact factor: 4.356

6.  Saccadic eye movements in different dimensions of schizophrenia and in clinical high-risk state for psychosis.

Authors:  Ilya Obyedkov; Maryna Skuhareuskaya; Oleg Skugarevsky; Victor Obyedkov; Pavel Buslauski; Tatsiana Skuhareuskaya; Napoleon Waszkiewicz
Journal:  BMC Psychiatry       Date:  2019-04-08       Impact factor: 3.630

7.  Positive and Negative Symptoms Are Associated with Distinct Effects on Predictive Saccades.

Authors:  Eleanor S Smith; Trevor J Crawford
Journal:  Brain Sci       Date:  2022-03-22

Review 8.  Brain-imaging studies of treatment-resistant schizophrenia: a systematic review.

Authors:  Elias Mouchlianitis; Robert McCutcheon; Oliver D Howes
Journal:  Lancet Psychiatry       Date:  2016-03-04       Impact factor: 27.083

9.  Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial Direct Current Stimulation in Neurological and Psychiatric Disorders.

Authors:  Felipe Fregni; Mirret M El-Hagrassy; Kevin Pacheco-Barrios; Sandra Carvalho; Jorge Leite; Marcel Simis; Jerome Brunelin; Ester Miyuki Nakamura-Palacios; Paola Marangolo; Ganesan Venkatasubramanian; Daniel San-Juan; Wolnei Caumo; Marom Bikson; André R Brunoni
Journal:  Int J Neuropsychopharmacol       Date:  2021-04-21       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.